NEW DELHI, June 1:Drug firm Claris Lifesciences today said it underwent an audit by the USFDA for Pharmacovigilance in the last week of May and has not received any observations.
“Claris Lifesciences along with its wholly-owned subsidiary Claris Injectables Ltd announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from May 29-31 with no observation (i483s),” the company said in a BSE filing.
(PTI)
Follow our WhatsApp channel